INTRODUCTION
Multiple myeloma (MM) is a heterogeneous disease, with survival duration ranging from a few months to more than 10 years. New, simple, and more robust biomarkers are needed to better dissect different disease categories within MM associated with different outcomes. 1 The International Staging System (ISS) is a simple risk stratification algorithm based on two parameters; high serum ␤ 2 -microglobulin level reflects high tumor mass and reduced renal function, and low serum albumin in MM is mainly caused by inflammatory cytokines such as interleukin-6 secreted by the myeloma microenvironment. The ISS score, defined in 2005, identifies three patient groups with different prognoses; the median overall survival (OS) was 62 months in the ISS stage I, 44 months in the ISS stage II, and 29 months in the ISS stage III groups (P Ͻ .001). 2 Chromosomal abnormalities (CA) detected by interphase fluorescent in situ hybridization (iFISH) are a key element to define the biologic features of MM. 3 In newly diagnosed MM (NDMM), standard-risk disease is characterized by the absence of del(17p), translocation t(4;14)(p16;q32), or translocation t(14;16)(q32;q23) and is associated with a median OS of 50.5 months, whereas high-risk disease is characterized by the presence of at least one of the previously mentioned abnormalities and is associated with a median OS of 24.5 months (P Ͻ .001). 4 Serum lactate dehydrogenase (LDH) is another relevant biomarker in MM. LDH level above the upper limit of normal denotes an increased disease aggressiveness and suggests high proliferation rate and/or the presence of tumor mass, in particular extramedullary and extraosseous disease. [5] [6] [7] [8] [9] Studies performed before the availability of novel agents showed that high LDH levels were associated with shorter OS. 5 Also in the era of novel agents, LDH confirmed its impact on survival. 6 To improve the predictive value of these risk factors evaluated per se, different combinations have been tested. Several studies that combined ISS stage and CA [mainly translocation t(4;14) and del(17p)] identified the following three risk categories: a low-risk group with a 5-year OS rate of a 60% to 70%; an intermediate-risk group with a 5-year OS rate of 40% to 60%; and a high-risk group with a 5-year OS rate of 15% to 40%. [10] [11] [12] Another study that combined ISS, CA, and LDH data defined four risk categories. In the very low-risk category, the 2-year OS rate was 93%; by contrast, in the very high-risk category, the 2-year OS rate was 55%, (Appendix Table A1 , online only). 13 These data strongly suggest the need for combining these prognostic factors to better stratify patients into homogeneous survival subgroups. Most of the data currently available were obtained in young patients who received autologous stem-cell transplantation (ASCT), with limited evaluation in elderly patients and patients ineligible for high-dose therapy. Here, we propose a simple model including ISS, CA, and LDH data to define subgroups of patients with different prognosis to better allow stratifications on clinical trials and data comparisons across studies. We assessed this new algorithm, the revised ISS (R-ISS), in 3,060 young and elderly patients with NDMM.
PATIENTS AND METHODS

Patients
A total of 4,445 patients with NDMM were enrolled onto 11 international, multicenter clinical trials, from 2005 to 2012 (Appendix Table A2 , online only). The results of these trials were previously reported (Clinical Trials.gov identifiers: NCT01346787, NCTC00551928, NCT01091831, NCT01093196, NCT01190787, NCT01063179, NCT01134484, NCT00461747, NCT00200681; Eudract: 2005-004714-32; Netherlands Trial Register: NTR213). [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] Patients gave written informed consent before entering the source trials, which were performed in accordance with the Declaration of Helsinki.
All patients received new drugs (immunomodulatory agents [IMIDs] or proteasome inhibitors [PIs]) in association with conventional chemotherapy as up-front treatment or incorporated into pretransplantation induction or post-transplantation maintenance strategies, except for the patients enrolled onto the Intergroupe Français du Myélome 2005-01 trial who were randomly assigned to vincristine, doxorubicin, and dexamethasone (VAD) induction and to VAD plus dexamethasone, cyclophosphamide, etoposide, and cisplatin before ASCT (Appendix Table A3 , online only).
Baseline data collected included the following: age, sex, ISS stage, CA detected by iFISH, and serum LDH level. Data about ISS stage, CA by FISH, and serum LDH were simultaneously available in 3,060 of 4,445 patients. The primary end point was OS, defined as the time from start of treatment until death as a result of any cause or until the last date the patient was known to be alive. The secondary end point was progression-free survival (PFS), defined as the time from start of treatment until progression or death as a result of any cause or until the last date the patient was known to be progression free.
ISS, CA, and LDH Analyses
ISS stage I was defined as serum ␤ 2 -microglobulin level less than 3.5 mg/L and serum albumin level Ն 3.5 g/dL. ISS stage II included all patients with neither stage I nor stage III disease. ISS stage III was defined as serum ␤ 2 -microglobulin level Ն 5.5 mg/L, irrespective of serum albumin level. 2 Bone marrow plasma cells (BMPCs) for iFISH analyses were enriched using anti-CD138 -coated magnetic MicroBeads and AutoMACS Pro Separator (Miltenyi Biotech, San Diego, CA) following manufacturer's instructions. BMPCs were then fixed in Carnoy's solution and stored at Ϫ20°C. Slides for iFISH were prepared using probes purchased from Cytocell (Cambridge, United Kingdom), Kreatech (Buffalo Grove, IL), and Vysis (Des Plaines, IL), according to manufacturer's instructions. The routine panel included baseline evaluation of del (13) , del(17p), and immunoglobulin H translocations. Nuclei were analyzed using a fluorescent light microscope. One hundred to 200 BMPC nuclei from each sample were scored. Del(17p), translocation t(4; 14), and translocation t(14;16) detected by iFISH were considered highrisk CA. Patients were considered positive for a given CA when it was present in a percentage higher than the cutoff threshold, defined by each local laboratory. Details of interlaboratory variability are reported in the Appendix (online only).
Serum LDH level was recorded at baseline and classified as normal or high according to the local laboratory definition of normal range. High LDH was defined as a serum level greater than the upper limit of normal range; normal LDH was defined as a serum level less than the upper limit of normal (Table 1) .
Statistical Analysis
An explorative analysis of the 3,060 patients for whom ISS, CA, and LDH data were simultaneously available was conducted. K-adaptive partitioning, 25 dedicated to censored survival data (minimax-based partitioning rule by logrank test), was used for ISS/CA/LDH grouping; this routine gave an optimal number of three subgroups (R-ISS I, II, and III). The OS and PFS curves were estimated using the Kaplan-Meier method and compared using the log-rank test. OS and PFS were then analyzed through the Cox proportional hazards model, comparing the following risk factors by the Wald test: age at diagnosis (Յ v Ͼ 65 years), sex (male v female), iFISH (high-risk v standard-risk CA), LDH (high v normal), ISS stage (II v I and III v I), and R-ISS grouping as defined by the recursive partitioning procedure. The effects of the baseline features (age, sex, and R-ISS) were also assessed by the multivariable Cox 
RESULTS
Patient Characteristics and Treatments
Median age was 62 years (range, 18 to 91 years); 65% of patients were Յ 65 years old, and 35% were older than age 65 years. In the overall population of 4,445 patients, 60% received ASCT (most of these patients were Յ 65 years old), 44% received PIs, and 66% received IMIDs; only 5% of patients did not receive any novel agent up front ( Table 2 ). Patient characteristics and treatments of the overall population were similar when compared with the 3,060 patients with ISS, CA, and LDH data available. Of note, of 1,171 patients with ISS stage I, 26% had high-risk CA and/or high LDH levels. Of 715 patients with ISS stage III, 57% had standard-risk CA and normal LDH levels ( Table 3) .
Individual ISS, CA, and LDH
The individual role of each predictor was initially evaluated in the total population of 4,445 patients. One thousand six hundred fifteen patients (36%) had ISS stage I, 1,630 (37%) had ISS stage II, and 987 (22%) had ISS stage III; 213 patients (5%) had missing data. At a median follow-up of 46 months, the 5-year OS rate was 77% for ISS stage I, 62% for ISS stage II, and 47% for ISS stage III (P Ͻ .001); the 5-year PFS rate was 49% for ISS stage I, 36% for ISS stage II, and 30% for ISS stage III (P Ͻ .001).
Two thousand seven hundred eighteen patients (61%) had standard-risk CA, 851 patients (19%) had high-risk CA, and 876 patients (20%) had missing data. The 5-year OS rate was 69% in the standard-risk group and 50% in the high-risk group (P Ͻ .001), whereas the 5-year PFS rates were 45% and 24% (P Ͻ .001), respectively.
Three thousand four hundred forty-three patients (77%) had a normal LDH level, 530 patients (12%) had a high LDH level, and 472 patients (11%) had missing data. The 5-year OS rate was 68% for patients with normal LDH and 47% for patients with high LDH (P Ͻ .001), whereas the 5-year PFS rates were 42% and 31% (P ϭ .004), respectively.
Combined ISS, CA, and LDH
The K-adaptive partitioning was performed in 3,060 patients with ISS, CA, and LDH data. The following three ISS/CA/LDH groups were identified (Table 1) : 871 patients (28%) with R-ISS stage I, (ISS stage I, no high-risk CA, and normal LDH); 295 patients (10%) with R-ISS stage III (ISS stage III plus high-risk CA or high LDH); and 1,894 patients (62%) with R-ISS stage II (all the other ISS/CA/LDH combinations).
At a median follow-up of 46 months, the 5-year OS was 82% for R-ISS stage I, 62% for R-ISS stage II, and 40% for R-ISS stage III, with a median OS time of not reached for R-ISS stage I, 83 months for R-ISS stage II, and 43 months for R-ISS stage III (Fig 1) . The 5-year PFS rate was 55% for R-ISS stage I, 36% for R-ISS stage II, and 24% for R-ISS stage III, with a median PFS time of 66 months for R-ISS stage I, 42 months for R-ISS stage II, and 29 months for R-ISS stage III (Fig 2) .
In the univariable Cox analysis, the risk of death was increased for ISS stage II versus I (hazard ratio [HR], 2.39) and stage III versus I (HR, 4.68). Similarly, the risk of death was higher for high-risk CA 
‫ء‬
Seven hundred twenty-two patients received immunomodulatory agents and proteasome inhibitors and were counted twice.
†Five hundred ten patients received immunomodulatory agents and proteasome inhibitors and were counted twice. Fig 2) .
In the multivariable Cox model for OS, including age, sex, and R-ISS, the risk of death was increased for age more than 65 years (HR, 1.32; 95% CI, 1.14 to 1.52; P Ͻ .001), male sex (HR, 1.16; 95% CI, 1.02 to 1.33; P ϭ .029), R-ISS stage II versus I (HR, 3.59; 95% CI, 2.68 to 4.80; P Ͻ .001), and R-ISS stage III versus I (HR, 9.64; 95% CI, 6.24 to 14.88; P Ͻ .001). In the multivariable Cox model for PFS, the risk of progression was higher for age greater than 65 years (HR, 1.57; 95% CI, 1.42 to 1.75; P Ͻ .001), R-ISS stage II versus I (HR, 1.99; 95% CI, 1.61 to 2.37; P Ͻ .001), and R-ISS stage III versus I (HR, 3.37; 95% CI, 2.54 to 4.56; P Ͻ .001).
Subgroup analyses for PFS and OS were also performed. The R-ISS staging system confirms its prognostic role in patients younger and older than 65 years of age (Appendix Fig A1, online only) as well as in patients who did and who did not receive ASCT, PIs, and IMIDs (Fig 3) .
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DISCUSSION
In this study, the most common prognostic tools (ISS stage, CA, and serum LDH level) were combined to define a simple, reliable, and pragmatic risk stratification of patients with NDMM. The R-ISS allowed a clear identification of the following three survival patterns through a simplified rule: R-ISS stage I includes ISS stage I, no highrisk CA, and normal LDH; R-ISS stage III includes ISS stage III with high-risk CA and/or high LDH levels; R-ISS stage II includes all the remaining conditions. Patients with R-ISS stage I, II, and III had 5-year OS rates of 82%, 62%, and 40%, respectively.
We initially evaluated the prognostic power of each single component of the R-ISS. The impact of ISS was confirmed for both OS (ISS stage III v I: HR, 4.68) and PFS (ISS stage III v I: HR, 2.18). As for CA, the presence of del(17p), translocation t(4;14), or translocation t(14;16) commonly identifies high-risk patients with poor outcome, 3, 4 and our study confirmed their prognostic impact for both OS (HR, 2.03) and PFS (HR, 1.82). Consistent with previous studies, we found that high serum LDH level predicted worse OS (HR, 2.55) and PFS (HR, 1.34).
Subsequently, we developed the R-ISS algorithm that combines these three prognostic features. Our major aim was to create a simple and easily applicable model that combined validated and reliable disease-related prognostic factors. The combination of three different prognostic tools in the R-ISS allows a better evaluation of patient prognosis; approximately 26% of patients would have been wrongly allocated to a good-prognosis group if we had considered only one of these three factors.
In the univariable Cox analyses, we found that ISS stage III, high-risk CA, and elevated serum LDH were associated with a significantly poorer OS (HR from 2.03 to 4.68). Their combination in the R-ISS improved the stratification and the impact on OS (HR from 3.68 to 9.95). The prognostic impact of R-ISS on OS was confirmed independently of age and therapy.
To define the three R-ISS stages. we did not use the classical recursive partitioning, which is a multivariable statistical method based on a binary tree representation, because it can easily manage categorical but not continuous variables. 26 Conversely, we adopted K-partitioning, a new technique that can manage censored survival data. K-partitioning provides minimal-based partitioning rules by log-rank test and finds an optimal set of cutoff points, and the number of groups does not need to be established in advance. 25 Previous studies have combined different prognostic tools (Appendix Table A1 ). [10] [11] [12] [13] Compared with other studies, the R-ISS has been developed in a larger sample size of 3,060 patients, including both young and elderly patients. In the other studies, the majority of patients were in the low-risk group (42% to 58%) [10] [11] [12] [13] ; in our analysis, 62% of patients were in the intermediate-risk group, whereas 28% were in the low-risk group and 10% were in the high-risk group. This distribution may explain the slightly better survival dissection among the different groups in our study, with HR for OS ranging from 3.68 to 9.95. We based our staging system on validated, simple, easily applicable, and reliable disease-related prognostic factors. There are novel, alternative approaches, such as gene expression profiling and single nucleotide polymorphisms, currently used for a detailed molecular analysis of MM. Yet, studies including gene expression profiling and single nucleotide polymorphism analyses showed inconsistent results, and further validation to achieve a more general consensus is still necessary. [27] [28] [29] In addition, these techniques are quite complex and expensive, which limits their routine use.
In our study, 95% of patients received novel agents. Although this was not the objective of our analysis, our results showed an improvement in OS with novel therapies across prognostic subgroups. In the original ISS study including patients worldwide treated from 1981 to 2002, with minimal exposure to any novel agents, the median OS was 62 months for patients with ISS stage I, 44 months for patients with ISS stage II, and 29 months for patients with ISS stage III. In our analysis, the median OS was not reached for patients with ISS stage I, 87 months for patients with ISS stage II, and 56 months in patients ISS stage III. 2 Our study has some limitations. We included only patients enrolled onto experimental trials (65% Ͻ 65 years old). We excluded some patients from the final analysis as a result of the lack of baseline data; in addition, information about chromosome 1 abnormalities was not collected in all trials, and thus we could not include this prognostic parameter. There was no interlaboratory standardization of FISH analysis, and heterogeneous cutoff levels for LDH were used in the different trials. In our model, we did not include host-related prognostic factors such as age, performance status, and comorbidities, which still play an important role in defining patient prognosis. The relatively short median follow-up time is another limitation. Furthermore, we used a single-step modeling approach, without splitting the series into training and validation autonomous sets. The lack of a real validation sample can be a limitation of the analysis. Nevertheless, both the large sample size and the homogeneity of the main clinical characteristics were expected to minimize the risk of data overfitting.
Future analyses will try to overcome such limitations and will validate this new risk stratification in population-based studies, including a higher proportion of elderly patients. The European Myeloma Network will also focus on FISH standardization in MM, and future efforts will be directed to combine both disease-related and patient-related factors to develop a more comprehensive prognostic evaluation.
In conclusion, there is a clear need for a better differentiation of patients with MM. MM can no longer be considered a single disease, but a mix of different disease entities. Today, new treatments are available, and survival of patients with MM has significantly improved. In clinical practice, a better definition of MM subgroups is essential to provide more effective personalized therapies. The R-ISS staging system is a new risk stratification algorithm with an improved prognostic power compared with the individual ISS, CA, and LDH parameters. It includes simple, reliable, and widely used prognostic markers, and it allows the identification of three different MM entities with clearly different outcomes.
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